Cours ContraVir Pharmaceuticals Inc Nasdaq
Actions
US21234W2026
Recherche biotechnologique et médicale
CA 2024 * | - | CA 2025 * | - | Capitalisation | 7,99 M 7,23 M |
---|---|---|---|---|---|
Résultat net 2024 * | -51 M -46,13 M | Résultat net 2025 * | -76 M -68,75 M | VE / CA 2024 * | - |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | - |
PER 2024 * |
-0,14
x | PER 2025 * |
-
| Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 99,69% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 01/01/16 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 03/10/19 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 15/05/13 |
Timothy Block
BRD | Director/Board Member | 69 | 26/11/13 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 27/06/22 |
Varia. 1 janv. | Capi. | |
---|---|---|
-1,43% | 104 Md | |
+8,96% | 105 Md | |
+4,40% | 22,94 Md | |
-12,15% | 22,34 Md | |
-4,36% | 19,25 Md | |
-39,98% | 17,08 Md | |
-10,04% | 16,96 Md | |
+6,79% | 14,16 Md | |
+38,61% | 12,63 Md |